Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma

Figure 3

Tumor perfusion at peak enhancement. Representative images of contrast enhanced ultrasonography at peak enhancement in group 1 (panels A and B), group 2 (panels C and D) and group 3 (panels E and F) at day + 5 (panels A, C and E) and at day +13 (panels B, D and F). Corresponding B-mode images are shown. At day +13, necrotic areas are present in group 1 (placebo group) and group 2 (sorafenib-placebo-sorafenib treatment) tumors whereas all tumor areas in group 3 tumors (sorafenib treatment stopped at day +5) are perfused, which might be speculated to derive from overstimulation of neoangiogenesis.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us